Lipocine (LPCN) Announces Launch of Public Offering of Common Stock, Warrants
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/30/2026
- Wall St set for higher open as soft inflation data eases rate-hike fears
- Equity positioning stays overweight, but summer extremes have eased: Barclays
- Oil gains as stalled US-Iran talks trump supply recovery
- Moderna: Citi says oncology optimism is priced in, cuts rating to sell
- Anthropic prospectus shows $2T IPO ambition, warns of AI 'existential risk'
- Salesforce agrees to acquire AI research platform Listen Labs
- Workday cuts 2.5% of workforce, revises GAAP margin outlook
- S&P 500 flat as higher bond yields counter tech optimism
- HPE raises networking revenue outlook, secures $1.2B Vultr order
- Mattel names Roger Lynch as chairman and CEO, replacing Ynon Kreiz
Lipocine Announces Launch Of Public Offering Of Common Stock And Warrants
November 13, 2019 4:00 PM ESTSALT LAKE CITY, Nov. 13, 2019 /PRNewswire/ -- Lipocine Inc. (NASDAQ: LPCN), a clinical-stage biopharmaceutical company focused on metabolic and endocrine disorders, today announced the launch of a public offering of units consisting of shares of its common stock (or pre-funded warrants) and warrants to purchase its common stock. The shares of common stock (or pre-funded warrants) and warrants comprising the units are... More
